A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Osteoporosis, Postmenopausal

Treatments: Drug: denosumab; Drug: placebo; Drug: open-label denosumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT01457950

114163

Details and patient eligibility

About

The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.

Enrollment: 135 patients

Sex: Female

Ages: 60 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ambulatory Korean postmenopausal women with osteoporosis
• greater than 5 years postmenopausal
• aged 60 to 90 years old
• absolute bone mineral density value consistent with a T-score less than -2.5 and greater than or equal to - 4.0 at the either the lumbar spine or total hip, as measured by dual energy x-ray absorptiometry. Subjects with a T-score less than -4.0 are at very high risk for fracture and will be excluded.

Exclusion criteria

• previous or current metabolic bone disease, Paget's or Cushing's disease, or hyperprolactinemia
• current hypo- or hyperparathyroidism or hypo- or hyperthyroidism unless on stable thyroid replacement therapy and TSH level meets criteria
• rheumatoid arthritis
• cirrhosis of the liver or unstable liver disease or ALT or AST greater than or equal to 2.0 times the upper limit of normal, or alkaline phosphatase and bilirubin greater than or equal to 1.5 times the upper limit of normal
• medications used to treat osteoporosis, defined for type and duration of use, and including IV and oral bisphosphonates
• medications that affect bone metabolism including parathyroid hormone or derivatives; anabolic steroids or testosterone; glucocorticosteroids; systemic hormone replacement therapy; selective estrogen receptor modulators; tibolone, calcitonin, and calcitriol or vitamin D derivatives; other bone active drugs including anticonvulsives (but not benzodiazepines) and heparin; chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, and gonadotropin-releasing hormone agonists
• malignancy within 5 years except certain resected types
• malabsorption syndrome or gastrointestinal disorders associated with malabsorption
• abnormal calcium level
• vitamin D deficiency
• any laboratory abnormality that will prevent the subject from completing the study or interfere with interpretation of study results
• severe renal impairment or on dialysis
• impaired immune system or subject is taking immunosuppressants
• oral or dental conditions including current or past history of osteomyelitis or osteonecrosis of the jaw; active dental or jaw condition with requires oral surgery; planned invasive dental procedure; un-healed dental or oral surgery
• any disorder that compromises the ability of the subject to give written informed consent or to comply with study procedures
• any physical or psychiatric disorder that will prevent the subject from completing the study or interferes with study results
• known to have tested positive for HIV
• less than two lumbar vertebrae evaluable for DXA measurements
• height, weight, or girth that may preclude accurate DXA measurements
• drug or alcohol abuse within 12 months that interferes with understanding or completing the study
• known sensitivity to mammalian cell-derived drug products
• use of an investigational drug or device within 30 days of enrollment or currently receiving other investigational agent(s)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

135 participants in 3 patient groups, including a placebo group

Arm 1

Experimental group

Description:

denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase

Treatment:

Drug: denosumab

Arm 2

Placebo Comparator group

Description:

placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase

Treatment:

Drug: placebo

Arm 3

Experimental group

Description:

open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase

Treatment:

Drug: open-label denosumab